Table 1.
Description of the groups that participated in the study.
| Variables | n |
|---|---|
| Main activity in hospital (GECOP group leader) | |
| Surgery, PSM exclusively | 18 |
| Surgery, HBP surgery | 4 |
| Surgery, Upper GI | 3 |
| Surgery, Surgical Oncology | 2 |
| Surgery, Others | 5 |
| Gynecol Oncol | 1 |
| Type of hospital | |
| Public and reference for oncological complex surgeries | 15 |
| Public and not reference for oncological complex surgeries | 8 |
| Private | 10 |
| Hospital size (beds) | |
| >750 | 10 |
| 500–750 | 8 |
| 250–500 | 6 |
| <250 | 9 |
| CRS + HIPEC every year | |
| >60 | 3 |
| 40–60 | 5 |
| 20–40 | 17 |
| <20 | 8 |
| Patients diagnosed with ovarian cancer (%) | |
| >75 | 1 |
| 50–75 | 7 |
| 25–50 | 11 |
| <25 | 14 |
| CRS + HIPEC in ovarian cancer | |
| Up-front | 11 |
| Interval Cytoreductive Surgery | 22 |
| Role of Gynecologist Oncologist and Surgical Oncologist | |
| Gynecologist Oncologist leads the unit | 8 |
| Leadership is shared | 7 |
| Surgical oncology leads the unit | 12 |
| There is no cooperation | 6 |
| Position of the Medical Oncologist at CRS + HIPEC | |
| Collaborator and in favor of the CRS + HIPEC | 17 |
| Collaborator but NOT in favor | 15 |
| Non-cooperative | 11 |